成骨与溶骨性骨转移机制差异及靶向药物进展  

Differences of osteoblastic and osteolytic bone metastases in molecular mechanisms and the advances in their targeted therapy

作　　者：瓦俄 方珏敏[1] 许青[1] 

机构地区：[1]同济大学附属第十人民医院肿瘤科,上海200072

出　　处：《现代肿瘤医学》2017年第22期3699-3703,共5页Journal of Modern Oncology

基　　金：上海市科委生物医药领域科技支撑项目(编号:16431903202)

摘　　要：多种癌症会转移到骨骼,导致溶骨性或成骨性骨损伤。不同的分子机制导致骨转移表型的差异。参与溶骨性骨转移(以乳腺癌为例)的分子包括甲状旁腺激素相关蛋白、转化生长因-β。而成骨性骨转移(以前列腺癌为例)中内皮素-1和形态蛋白质等在骨形成中发挥重要的作用。了解骨转移不同表型的分子机制的差别对临床医生很重要,可为骨转移的治疗提供潜在的分子靶点。本文对两种骨转移机制及靶向药物的最新进展进行了综述,旨在探讨不同类型骨转移的生物学行为,了解潜在的靶向药物,提高骨转移的治疗效果。Bone metastases occur in several kinds of cancers.Cancers which metastasize to bone usually generate osteolytic or osteoblastic bone lesions.The two phenotypes of bone metastases,bone destruction and bone formation have different molecular mechanisms.For example,molecules participated in osteolytic bone metastases include parathyroid hormone-related protein,transforming growth factor-β,while endothelin-1 and morphogenetic proteins,etc.play a more important role in osteoblastic lesions.Advances in our understanding of the molecular and cellular mechanisms may lead to the development of novel therapeutic options.Here we review the differences of bone metastases mechanisms between two phenotypes to help clinicians to understand the underlying mechanisms,behaviors and therapies in development and currently available for bone metastases.

关 键 词：骨转移 分子特征 靶向治疗 

分 类 号：R730[医药卫生—肿瘤]